JP2007514752A5 - - Google Patents

Download PDF

Info

Publication number
JP2007514752A5
JP2007514752A5 JP2006545462A JP2006545462A JP2007514752A5 JP 2007514752 A5 JP2007514752 A5 JP 2007514752A5 JP 2006545462 A JP2006545462 A JP 2006545462A JP 2006545462 A JP2006545462 A JP 2006545462A JP 2007514752 A5 JP2007514752 A5 JP 2007514752A5
Authority
JP
Japan
Prior art keywords
aib
acc
phe
ala
2nal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2006545462A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007514752A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/042389 external-priority patent/WO2005058252A2/en
Publication of JP2007514752A publication Critical patent/JP2007514752A/ja
Publication of JP2007514752A5 publication Critical patent/JP2007514752A5/ja
Ceased legal-status Critical Current

Links

JP2006545462A 2003-12-16 2004-12-16 Ｇｌｐ−１医薬組成物 Ceased JP2007514752A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52993203P 2003-12-16 2003-12-16
PCT/US2004/042389 WO2005058252A2 (en) 2003-12-16 2004-12-16 Glp-1 pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010224218A Division JP2011001381A (ja) 2003-12-16 2010-10-01 Ｇｌｐ−１医薬組成物

Publications (2)

Publication Number Publication Date
JP2007514752A JP2007514752A (ja) 2007-06-07
JP2007514752A5 true JP2007514752A5 (https=) 2010-05-13

Family

ID=34700069

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006545462A Ceased JP2007514752A (ja) 2003-12-16 2004-12-16 Ｇｌｐ−１医薬組成物
JP2010224218A Pending JP2011001381A (ja) 2003-12-16 2010-10-01 Ｇｌｐ−１医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010224218A Pending JP2011001381A (ja) 2003-12-16 2010-10-01 Ｇｌｐ−１医薬組成物

Country Status (7)

Country Link
US (1) US7521527B2 (https=)
EP (1) EP1694278A4 (https=)
JP (2) JP2007514752A (https=)
AR (1) AR047776A1 (https=)
CA (1) CA2550695A1 (https=)
TW (1) TWI353250B (https=)
WO (1) WO2005058252A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60335608D1 (de) * 2002-02-27 2011-02-17 Pharmain Corp Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
WO2005112977A2 (en) * 2004-04-23 2005-12-01 Pharmain, Ltd. Compositions for treatment with glucagon-like peptide, and methods of making and using the same
CN101258163B (zh) 2005-06-30 2013-08-21 益普生制药股份有限公司 Glp-1药物组合物
PL1971362T3 (pl) 2005-08-19 2015-05-29 Amylin Pharmaceuticals Llc Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
KR101529318B1 (ko) 2005-12-19 2015-06-16 파마인 코포레이션 치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
MX2009006942A (es) * 2006-12-29 2009-11-09 Ipsen Pharma Sas Composiciones farmaceuticas de glp-1.
CN101668535B (zh) * 2006-12-29 2017-07-28 益普生制药股份有限公司 Glp‑1药物组合物
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
EP2200626A4 (en) * 2007-09-07 2012-02-15 Ipsen Pharma Sas ANALOGUE OF EXENDIN-4 AND EXENDIN-3
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
WO2009139855A2 (en) * 2008-05-14 2009-11-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of somatostatin-dopamine conjugates
WO2009143285A2 (en) 2008-05-21 2009-11-26 Amylin Pharmaceuticals, Inc. Exendins to lower cholestrol and triglycerides
WO2010016936A1 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
JP5486690B2 (ja) 2009-11-16 2014-05-07 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ メラノコルチン受容体リガンドの医薬組成物
CN102821775B (zh) * 2010-03-15 2014-10-22 益普生制药股份有限公司 生长激素促分泌素受体配体的药物组合物
EP2384733B1 (de) 2010-05-07 2016-07-27 Ivoclar Vivadent AG Antimikrobielle Dentalwerkstoffe
TWI523863B (zh) 2012-11-01 2016-03-01 艾普森藥品公司 體抑素－多巴胺嵌合體類似物
EP2914276A4 (en) 2012-11-01 2016-07-13 Ipsen Pharma Sas SOMATOSTATIN ANALOGA AND DIMERE OUT
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
JP2583257B2 (ja) 1986-05-05 1997-02-19 ザ・ジェネラル・ホスピタル・コーポレーション インシュリン向性ホルモン
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US6221958B1 (en) * 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
CA2137206A1 (en) 1993-12-09 1995-06-10 John A. Galloway Glucagon-like insulinotropic peptides, compositions and methods
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US20010006943A1 (en) * 1994-12-23 2001-07-05 Ejvind Jensen Protracted GLP-1 compositions
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
JP2001503963A (ja) 1996-02-06 2001-03-27 イーライ・リリー・アンド・カンパニー 糖尿病治療
US6264970B1 (en) * 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
DE19629640C1 (de) 1996-07-23 1997-08-28 Metallgesellschaft Ag Verfahren zur Herstellung von kristallinem D-Sorbit
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US5981488A (en) 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
US6663899B2 (en) * 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
EP1061946B1 (en) 1998-02-27 2004-04-28 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
EP1056774A1 (en) 1998-02-27 2000-12-06 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
WO1999048519A1 (en) * 1998-03-20 1999-09-30 Takeda Chemical Industries, Ltd. Sustained-release preparation of physiologically active polypeptide and production thereof
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
FR2777283B1 (fr) * 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
RU2205188C2 (ru) * 1998-06-30 2003-05-27 Ново Нордиск А/С Затравочные кристаллы для получения пептидов или протеинов
US6720407B1 (en) * 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
CZ295044B6 (cs) * 1998-12-07 2005-05-18 Societe De Conseils De Recherches Et D'application Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
EP1992641A3 (en) * 1998-12-07 2009-07-29 Ipsen Pharma GLP-1 analogues
US6902744B1 (en) * 1999-01-14 2005-06-07 Amylin Pharmaceuticals, Inc. Exendin agonist formulations and methods of administration thereof
WO2001000223A2 (en) 1999-06-25 2001-01-04 Minimed Inc. Multiple agent diabetes therapy
US6541225B1 (en) * 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
AU2001228327A1 (en) 2000-01-31 2001-08-14 Novo-Nordisk A/S Crystallisation of a glp-1 analogue
US6844321B2 (en) * 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
JP4716641B2 (ja) * 2000-06-16 2011-07-06 イーライ リリー アンド カンパニー グルカゴン様ペプチド−１類似体
AU2002308706A1 (en) * 2001-06-01 2002-12-16 Eli Lilly And Company Glp-1 formulations with protracted time action
WO2003002136A2 (en) * 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
KR20040054729A (ko) * 2001-10-18 2004-06-25 브리스톨-마이어스 스큅 컴퍼니 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
MXPA04003569A (es) 2001-10-19 2004-07-23 Lilly Co Eli Mezclas bifasicas de glp-1 e insulina.

Similar Documents

Publication Publication Date Title
JP2007514752A5 (https=)
RU2485135C2 (ru) Соединения оксинтомодулина (варианты), фармацевтическая композиция на их основе, способы лечения и профилактики ожирения и сопутствующих заболеваний (варианты) и лекарственное средство (варианты)
CN1247260C (zh) 甲状旁腺素类似物
JP3787242B2 (ja) グルカゴン様ペプチド−１（７−３７）の類似体である新規ペプチド化合物、それらの製造法、およびそれらを含有する製剤組成物
US4410512A (en) Combinations having synergistic pituitary growth hormone releasing activity
CN1137898C (zh) 甲状旁腺素的类似物
Plucinska et al. Multiple binding modes for the receptor-bound conformations of cyclic AII agonists
EP2019118B1 (en) Method for synthesizing thymosins
MXPA03001721A (es) Peptidos ciclicos selectivos.
JP2009537624A5 (https=)
JPH05163298A (ja) 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
LU87495A1 (fr) Nouveaux derives peptidiques,leur preparation et leur utilisation omme medicaments
HUP0104579A2 (hu) GLP-1 analógok, ezeket tartalmazó gyógyászati készítmények, valamint a vegyületek alkalmazása
US4410513A (en) Synthetic peptides having pituitary growth hormone releasing activity
JP2013500990A5 (https=)
CA2040264A1 (en) Parathyroid hormone antagonists
JP2009108078A5 (https=)
JPH06504795A (ja) 新規アミリン拮抗剤ペプチドおよびその使用
KR100236413B1 (ko) Grf(쥐이알에프) 유사체 xi
CN102239176A (zh) 用于制备治疗性肽的方法
PT94553A (pt) Processo para a preparacao de novos analogos ii de peptidos intestinais vasoactivos (vip) e de composicoes farmaceuticas que os contem
JP6231882B2 (ja) 放射性コンジュゲーション方法
JP2008517998A5 (https=)
JP2008543733A (ja) 固相結合型サイモシンα−１およびその合成
CN1119650A (zh) 具有胃肠道运动刺激活性的胃动素样多肽